Biometrics

TheScientificWorldJOURNAL (ISSN 1537-744X)

Article Details

tag at del.icio.us Bookmark this Article Post a Comment Email a friend print document Home  
 
 
  Title: Update on the Treatment of Diabetic Retinopathy
  Authors:   Wilkinson-Berka, Jennifer L.; Miller, Antonia G.  
  Journal:   TheScientificWorldJOURNAL  
  Year:   2008  
  Volume:   8  
  Page Range:   98-120  
  Article Type:   Review Article  
  Handling Editor:   Mark Cooper  
  Domains:    Nephrology ,  Endocrinology ,  Neurology ,  Sensation & Perception  
  DOI:   10.1100/tsw.2008.25  
? Article clouds not enabled. Press the image to enable for this session.
  Keywords:   diabetic retinopathy, angiotensin, VEGF, corticosteroids, protein kinase C, advanced glycation end-products, growth hormone  
     
 
      Order Article [Related TSW Articles] [Export to EndNote] [Open Choice]  
     

 
      Abstract  
      Retinopathy is the most feared complication of diabetes, compromising quality of life in most sufferers. Almost all patients with type 1 diabetes will develop retinopathy over a 15- to 20-year period, and approximately 20–30% will advance to the blinding stage of the disease[1]. Greater than 60% of patients with type 2 diabetes will have retinopathy. This situation is highlighted by the frightening statistic that diabetic retinopathy (DR) remains the most common cause of vision impairment in people of working age in Western society. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 360 million people are projected to suffer from diabetes and its complications by 2030. Vision loss from diabetes is due to a number of factors, including haemorrhage from new and poorly formed blood vessels, retinal detachment due to contraction of deposited fibrous tissue, and neovascular glaucoma resulting in an increase in intraocular pressure. Diabetic macular oedema is now the principal cause of vision loss in diabetes and involves leakage from a disrupted blood-retinal barrier. In terms of treatment, there is clear evidence that strict metabolic and blood pressure control can lower the risk of developing DR and reduce disease progression. Laser photocoagulation and vitrectomy are effective in preventing severe vision loss in DR, particularly in the most advanced stages of the disease. However, both procedures have limitations. This review examines evidence from preclinical and clinical studies that shows that targeting inhibition of the renin-angiotensin system, vascular endothelial growth factor, corticosteroids, protein kinase C, growth hormone, and advanced glycation end-products are potential treatments for DR.  
     
Related articles in:
 
     

 
     
Comments Received             Post Your Comment Post a Comment
 
      sort comments by: [date posted]   [author name]     
     

omer khan

Posted 8th May 2010

 

ful text


 
     

Bo-Min Kim

Posted 9th July 2009

 

Please.


 
     

wang zhao-yang

Posted 21st February 2009

 

this is a excellent paper


 
     

dinesh

Posted 16th December 2008

 

i want more information


 
     

xuguangchang

Posted 22nd November 2008

 

I am very interested in this article.But I can not read it completely.I hope you can Email it to me.Thanks!


 
     

wenwenxuan

Posted 18th July 2008

 

I think it's useful.


 
     
Post your comments about this paper
No need to register
All comment submissions are monitored. The editor reserves the right to amend or delete any comment. Please ensure your have provided your correct email address: You will receive an email with a link enabling you to edit your comment. Do not use this blog to order this article.
 
Your Full Name:
Your Contact Email:

Please ensure you have provided your correct email address

Comments:
  This Is CAPTCHA Image
For security reasons please enter
the numbers you see in the figure above:
   
 
         
     
tag at del.icio.us Bookmark this Article Post a Comment Email a friend print document Home